Book cover for Pharmacology and the Nursing Process

Pharmacology and the Nursing Process

Linda Lane Lilley, Shelly Rainforth Collins, Julie S. Snyder

ISBN #9780323087896

7th Edition

394 Questions

Group icon
2,697 Students Helped

Homework Questions

Right arrow
Summary
Learning Objectives
Key Concepts
Example Problems
Explanations
Common Mistakes

Summary

This chapter section on Drug Profiles in ophthalmic drugs provides an in-depth look at alpha blockers, beta blockers, and alkylating antineoplastic agents. It outlines each drug class’s mechanism of action, clinical applications, and the critical importance of understanding pharmacokinetic properties, drug interactions, and contraindications to optimize patient safety and therapeutic outcomes.

Learning Objectives

1

Describe the mechanism of action of alpha blockers, beta blockers, and alkylating agents.

2

Explain how alpha blockers and beta blockers are used therapeutically for conditions like hypertension, BPH, and myocardial oxygen demand reduction.

3

Analyze the role of alkylating agents in inhibiting cell proliferation through DNA cross-link formation.

4

Assess the importance of pharmacokinetic properties, drug interactions, and contraindications in optimizing therapeutic outcomes and ensuring patient safety.

Key Concepts

CONCEPT

DEFINITION

Alpha Blockers

Drugs that block alpha-adrenergic receptors, leading to vasodilation and smooth muscle relaxation. They are used to manage conditions such as hypertension and benign prostatic hyperplasia (BPH).

Beta Blockers

Medications that inhibit beta-adrenergic receptors, reducing heart rate and contractility to decrease myocardial oxygen demand. They may vary in receptor selectivity and intrinsic sympathomimetic activity.

Alkylating Agents

A class of antineoplastic agents that work by forming covalent bonds with DNA molecules, creating cross-links that inhibit DNA replication and cell proliferation.

Pharmacokinetics

The study of how drugs are absorbed, distributed, metabolized, and excreted in the body.

Drug Interactions

The effects that may occur when a drug is taken in combination with other drugs, potentially altering the effectiveness or safety of one or more of the drugs.

Contraindications

Specific situations or conditions where a particular drug should not be used, as it may be harmful to the patient.

Example Problems

Example 1

The ophthalmologist has given a paticnt a dose of ocular atropine drops before an eye examination. Which statement by the nurse accurately explains to the paticnt the reason for these drops? a "Ihese drops will cause the surface of your eye to become numb so that the doctor can do the examination." b "These drops are used to check for any possible forcign bodies or corneal defects that may be in your eye." c "Ihese drops will reduce your tear production for the eye examination." d "Ihese drops will cause your pupils to dilate, which makes the eye examination easier."

Example 2

When assessing a patient who is receiving a direct-acting cholinergic eyedrop as part of treatment for glaucoma, the nurse anticipates that the drug affects the pupil in which way? a It causes mydriasis, or pupil dilation. b It causes miosis, or pupil constriction. c It changes the color of the pupil. d It causes no change in pupil size.

Example 3

During patient teaching regarding self-administration of ophthalmic drops, which statement by the nurse is correct? a "Hold the eyedrops over the cornea, and squeeze out the drop." b "Apply pressure to the lacrimal duct area for 5 minutes after administration." c "Be sure to place the drop in the conjunctival sac of the lower eyelid." d "Squeeze your eyelid closed tightly after placing the drop into your eye."

Example 4

When the nurse is providing teaching about eye medications for glaucoma, the nurse tells the patient that miotics help glaucoma by which mechanism of action? a Decreasing intracranial pressure b Decreasing intraocular pressure c Increasing tear production d Causing pupillary dilation

Example 5

During the assessment of a glaucoma patient who has newly prescribed carbonic anhydrase inhibitor eyedrops, the nurse would report a history of which condition? a Allergy to sulfa drugs b $\quad$ 1)ecreased renal function c Diabetes mellitus d Hypertension
Scroll left
Scroll right

Step-by-Step Explanations

QUESTION

How does tamsulosin help manage BPH symptoms?

STEP-BY-STEP ANSWER:

Step 1: Tamsulosin targets and blocks alpha-adrenergic receptors in the smooth muscles of the prostate and bladder neck.
Step 2: This blockade causes relaxation of the smooth muscle tissue.
Step 3: The relaxation improves urinary flow and reduces the symptoms of benign prostatic hyperplasia.
Final Answer: Tamsulosin alleviates BPH symptoms by relaxing smooth muscles through alpha-adrenergic receptor blockade, thereby improving urine flow.

Alpha Blockers (e.g., Tamsulosin)

QUESTION

How do beta blockers reduce myocardial oxygen demand?

STEP-BY-STEP ANSWER:

Step 1: Beta blockers inhibit beta-adrenergic receptors in the heart.
Step 2: This results in a decrease in heart rate and cardiac contractility.
Step 3: The reduced heart activity lowers the myocardial oxygen demand.
Final Answer: Beta blockers decrease myocardial oxygen demand by reducing heart rate and contractility through the inhibition of beta-adrenergic receptors.

Beta Blockers

QUESTION

What is the mechanism by which alkylating agents inhibit cell proliferation?

STEP-BY-STEP ANSWER:

Step 1: Alkylating agents interact with DNA by forming covalent bonds.
Step 2: These bonds result in the formation of cross-links between DNA strands.
Step 3: The DNA cross-links hinder DNA replication and transcription.
Final Answer: Alkylating agents inhibit cell proliferation by forming DNA cross-links which interfere with DNA replication and transcription, leading to cell death.

Alkylating Agents

Scroll left
Scroll right

Common Mistakes

  • Confusing the roles of alpha and beta blockers, especially regarding their specific receptor targets and clinical applications.
  • Overlooking the significance of pharmacokinetic properties and drug interactions when assessing drug efficacy and safety.
  • Assuming that all alkylating agents work identically, without recognizing their unique profiles and potential side effects.
  • Failing to differentiate between intrinsic sympathomimetic activity of various beta blockers, which can lead to misinterpretation of their therapeutic benefits.